NEUROONE MEDICAL TECHNOLOGIES Corp
No enriched coverage for $NMTC in the last 7 days.
No SEC Form 4 filings for $NMTC in the last 30 days.
See all $NMTC insider activity →EQS-News: NeuroOne Medical Technologies / Key word(s): Science NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED Platform 30.07.2026 / 22:11 CET/CEST The issuer is solely responsible for the content of this announcement.
NeuroOne Medical Technologies (Nasdaq: NMTC) said physicians at Mayo Clinic Florida treated 25 drug-resistant focal epilepsy patients with the OneRF brain ablation system after SEEG monitoring. The company reported rare short-term effects, no serious long-term complications, reduced seizure frequency, and improved patient-reported quality of life, citing real-world experience.
NeuroOne Medical Technologies (Nasdaq: NMTC) said it is collaborating with Mayo Clinic on a pediatric diffuse midline glioma research program supported by a grant from the Children’s Cancer Research Fund. The project will use NeuroOne’s investigational neural drug delivery device to test a combination approach aimed at improving intratumoral drug retention, starting with large animal studies.
Recent NMTC coverage spans financial news, technology and market movers.
The announcement is primarily scientific/marketing support for StereoCED, with a stated FY-end target for research and investigational study device availability.
Real-world physician experience supports NeuroOne’s OneRF diagnosis-to-therapy narrative, but it is not a new regulatory approval or controlled trial datapoint.
The deal is a positive validation signal for NeuroOne’s drug-delivery platform, but it is preclinical/early-stage and lacks financial terms.
Index inclusion can drive incremental passive/benchmark demand and improve liquidity/visibility, but it is not an operating or financial catalyst.
NeuroOne Medical Technologies Corp (NMTC) reports strong fiscal year 2025 revenue growth, FDA clearance for new device, and capital raise, indicating positive operational momentum. However, challenges such as NASDAQ compliance and certification hurdles remain. The stock shows a bullish sentiment with a relevance score of 1.0.
alphai scores every news story that mentions NMTC with an AI model for sentiment and relevance, and aggregates insider trades from NEUROONE MEDICAL TECHNOLOGIES Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
EQS-News: NeuroOne Medical Technologies / Key word(s): Science NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED Platform 30.07.2026 / 22:11 CET/CEST The issuer is solely responsible for the content of this announcement.
2 min readNeuroOne Medical Technologies (Nasdaq: NMTC) said physicians at Mayo Clinic Florida treated 25 drug-resistant focal epilepsy patients with the OneRF brain ablation system after SEEG monitoring. The company reported rare short-term effects, no serious long-term complications, reduced seizure frequency, and improved patient-reported quality of life, citing real-world experience.
3 min readNeuroOne Medical Technologies (Nasdaq: NMTC) said it is collaborating with Mayo Clinic on a pediatric diffuse midline glioma research program supported by a grant from the Children’s Cancer Research Fund. The project will use NeuroOne’s investigational neural drug delivery device to test a combination approach aimed at improving intratumoral drug retention, starting with large animal studies.
3 min readNeuroOne Medical Technologies (Nasdaq: NMTC) said it is expected to be added to the Russell Microcap Index based on preliminary FTSE Russell index additions lists published May 22, May 29 and June 5, 2026. The reconstituted Russell indexes take effect after the US market close on June 26, 2026, as part of the first semi-annual 2026 reconstitution.
2 min readNeuroOne Medical Technologies Corp (NMTC) reported a significant increase in product revenue of 163% to $9.1 million for fiscal year 2025, alongside improved gross margins and reduced operating expenses. The company also secured FDA 510(k) clearance for its OneRF trigeminal nerve ablation system and strengthened its balance sheet with an $8.2 million capital raise. Despite these successes, NMTC faces challenges such as NASDAQ compliance, obtaining ISO 13485 certification, and establishing strategic partnerships for its new platforms.
3 min readEDEN PRAIRIE, Minn., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC ) ( "NeuroOne" or the "Company" ) , a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will be ...
2 min readNeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.
2 min readNeuroOne Medical Technologies ( NASDAQ:NMTC ) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising to 53.9% from 34.1% in the third quarter of fiscal year 2024.
3 min readImage source: The Motley Fool.Thursday, Aug. 14, 2025 at 8:30 a.m. ETChief Executive Officer - David A. RosaContinue reading ...
3 min readNeuroOne Medical Technologies ( NASDAQ:NMTC ) , a med-tech company specializing in advanced thin film electrode and ablation systems for neurological disorders, reported Q3 FY2025 results on August 14, 2025. The earnings release showcased a material improvement in profitability, with earnings per ...
2 min read
